Compare RGCO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | OTLK |
|---|---|---|
| Founded | 1912 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 249.6M |
| IPO Year | 2005 | 2016 |
| Metric | RGCO | OTLK |
|---|---|---|
| Price | $21.60 | $0.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $22.70 | $2.50 |
| AVG Volume (30 Days) | 9.6K | ★ 3.6M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | 11.21 | ★ 55.91 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $95,334,212.00 | $8,146,123.00 |
| Revenue This Year | $11.06 | $1,430.98 |
| Revenue Next Year | $2.89 | $173.23 |
| P/E Ratio | $15.53 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $20.55 | $0.16 |
| 52 Week High | $27.17 | $2.54 |
| Indicator | RGCO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 37.67 |
| Support Level | $20.90 | $0.60 |
| Resistance Level | $22.21 | $0.72 |
| Average True Range (ATR) | 0.47 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 39.23 | 19.62 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.